| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
ADUS
Addus Homecare
|
Sep 02, 2026 | HOLD |
Strong Buy
+8.9% avg upside
19 analysts
|
$115.00
2.61% Downside
|
· | · |
|
HQY
Healthequity
|
Aug 28, 2026 | BUY |
Strong Buy
+16.6% avg upside
20 analysts
|
$105.00
6.65% Upside
|
+0.2% | · |
|
WAY
Waystar Holding Corp.
|
Aug 27, 2026 | BUY |
Strong Buy
+44.4% avg upside
30 analysts
|
$30.00
16.65% Upside
|
+3.7% | · |
|
VEEV
Veeva Systems
|
Aug 27, 2026 | HOLD |
Buy
-2.8% avg upside
38 analysts
|
$270.00
3.87% Downside
|
-1.4% | · |
|
AVAH
Aveanna Healthcare Holdings
|
Aug 14, 2026 | BUY |
Buy
-19.5% avg upside
18 analysts
|
$14.00
6.15% Upside
|
+8.9% | · |
|
PRVA
Privia Health Group
|
Aug 07, 2026 | BUY |
Strong Buy
+54.3% avg upside
26 analysts
|
$30.00
44.74% Upside
|
-8.7% | · |
|
OMDA
Omada Health, Inc.
|
Aug 06, 2026 | BUY |
Strong Buy
+16.3% avg upside
12 analysts
|
$24.00
2.87% Upside
|
+19.3% | · |
|
LFST
Lifestance Health Group
|
Aug 06, 2026 | BUY |
Strong Buy
-8.3% avg upside
15 analysts
|
$13.00
0.87% Upside
|
+20.4% | · |
|
SHC
Sotera Health
|
Aug 06, 2026 | BUY |
Strong Buy
+15.7% avg upside
13 analysts
|
$22.00
16.10% Upside
|
-0.4% | · |
|
EVH
Evolent Health
|
Aug 06, 2026 | BUY |
Strong Buy
+128.4% avg upside
19 analysts
|
$6.00
41.83% Upside
|
+25.4% | · |
|
DOCS
Doximity
|
Aug 06, 2026 | HOLD |
Buy
+36.8% avg upside
28 analysts
|
$30.00
13.89% Upside
|
+29.4% | · |
|
MDLN
Medline
|
Aug 05, 2026 | BUY |
Strong Buy
+29.6% avg upside
27 analysts
|
$47.00
29.49% Upside
|
-0.2% | · |
|
CERT
Certara
|
Aug 04, 2026 | HOLD |
Buy
+59.5% avg upside
22 analysts
|
$8.00
3.36% Downside
|
+3.9% | · |
|
BTSG
BrightSpring Health Services, Inc.
|
Aug 03, 2026 | BUY |
Strong Buy
+9.6% avg upside
20 analysts
|
$70.00
16.23% Upside
|
-2.2% | · |
|
TDOC
Teladoc
|
Jul 29, 2026 | HOLD |
Buy
+351.9% avg upside
38 analysts
|
$7.00
8.30% Upside
|
-29.2% | · |
|
IQV
IQVIA Holdings
|
Jul 29, 2026 | BUY |
Strong Buy
-7.3% avg upside
39 analysts
|
$270.00
2.43% Upside
|
+6.0% | · |
|
MEDP
Medpace Holdings
|
Jul 27, 2026 | HOLD |
Buy
-17.9% avg upside
17 analysts
|
$600.00
1.10% Upside
|
+0.6% | · |
|
HCSG
Healthcare Services
|
Jul 22, 2026 | HOLD |
Buy
+14.0% avg upside
13 analysts
|
$24.00
10.31% Upside
|
-4.8% | · |
|
ICLR
Icon
|
Jun 25, 2026 | BUY |
Strong Buy
+17.1% avg upside
26 analysts
|
$187.00
16.93% Upside
|
+0.3% | · |
|
PHR
Phreesia
|
Jun 22, 2026 | BUY |
Strong Buy
+44.7% avg upside
21 analysts
|
$14.00
18.12% Upside
|
+33.0% | · |
|
GDRX
GoodRx Holdings
|
Feb 27, 2025 | BUY |
Buy
+272.8% avg upside
28 analysts
|
$6.00
74.01% Upside
|
-29.1% | · |
|
HCAT
Health Catalyst
|
Feb 26, 2025 | HOLD |
Buy
+220.7% avg upside
15 analysts
|
$6.00
254.95% Upside
|
-67.8% | · |
|
AGL
Agilon Health
|
Feb 25, 2025 | BUY |
Buy
-22.7% avg upside
26 analysts
|
$3.50
95.95% Downside
|
-3.1% | · |
|
OPRX
OptimizeRx
|
Jan 08, 2025 | HOLD |
Strong Buy
+59.0% avg upside
9 analysts
|
$6.00
25.40% Downside
|
+46.9% | · |
|
MDRX
Veradigm
|
Mar 13, 2024 | BUY |
Buy
+207.5% avg upside
22 analysts
|
$11.00
134.14% Upside
|
-39.9% | · |
|
OTRKQ
Ontrak
|
May 11, 2022 | HOLD |
Hold
+21716566.7% avg upside
7 analysts
|
$2.00
1999900.07% Upside
|
· | · |
|
NUVB
Nuvation Bio
|
Nov 10, 2021 | BUY |
Strong Buy
+93.9% avg upside
17 analysts
|
$16.00
130.84% Upside
|
-85.2% | · |
|
ACH
Accendra Health
|
Feb 20, 2019 | HOLD |
Sell
+1313.6% avg upside
17 analysts
|
$7.00
498.38% Upside
|
+301.2% | · |
|
IBM
International Business Machines
|
May 19, 2017 | SELL |
Buy
-2.0% avg upside
42 analysts
|
$135.00
41.64% Downside
|
+3.5% | · |
|
MCK
McKesson
|
Aug 02, 2010 | BUY |
Strong Buy
-16.4% avg upside
29 analysts
|
— | +40.7% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.